The device is meant to treat atrial fibrillation patients who are unable to tolerate blood thinners to reduce stroke risk. It works by sealing the left atrial appendage — a small pouch connected to the heart’s upper left chamber — to prevent clots from forming in the area, the system said in a March 28 news release sent to Becker’s.
“The treatment option opens the door for many more patients who cannot be on blood thinners for even a short period. It also allows the LAA closure for different shapes and sizes,” said Ruby Satpathy, MD, an interventional cardiologist who implanted the device in a 75-year-old patient.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
